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Porcine reproductive and respiratory syndrome virus (PRRSV) is an arterivirus that shows a restricted in vivo tropism for
subsets of porcine macrophages, with alveolar macrophages being major target cells. The virus is associated with
respiratory problems in pigs of all ages and is commonly isolated on farms with porcine respiratory disease complex
(PRDC). Due to virus-induced macrophage death early in infection, PRRSV hampers the innate defence against pathogens
in the lungs. In addition, the virus might also directly affect the antimicrobial functions of macrophages. This study
examined whether interaction of European genotype PRRSV with primary alveolar macrophages (PAM) affects their
phagocytic capacity. Inoculation of macrophages with both subtype I PRRSV (LV) and subtype III PRRSV (Lena) showed
that the virus inhibits PAM phagocytosis. Similar results were obtained using inactivated PRRSV (LV), showing that initial
interaction of the virion with the cell is sufficient to reduce phagocytosis, and that no productive infection is required.
When macrophages were incubated with sialoadhesin- (Sn) or CD163-specific antibodies, two entry mediators of the
virus, only Sn-specific antibodies downregulated the phagocytic capacity of PAM, indicating that interaction with Sn, but
not CD163, mediates the inhibitory effect of PRRSV on phagocytosis. In conclusion, this study shows that European
genotype PRRSV inhibits PAM phagocytosis in vitro, through the interaction with its internalization receptor Sn. If similar
events occur in vivo, this interaction may be important in the development of PRDC, as often seen in the field.Introduction
Porcine reproductive and respiratory syndrome virus
(PRRSV) is the causative agent of porcine reproductive
and respiratory syndrome (PRRS), which has become one
of the most important diseases affecting swine industry
worldwide. PRRS is characterized by reproductive failure
in sows and gilts and respiratory problems in pigs of all
ages [1,2]. The annual cost of this disease is estimated at
664 million dollars in the USA alone [3], representing over
one-third of the total losses in swine industry attributed to
infectious diseases [4]. PRRSV is a small, enveloped, posi-
tive-stranded RNA virus that belongs to the genus Arteri-
virus, which is classified within the family of the* Correspondence: Hans.Nauwynck@Ugent.be
†Equal contributors
1Laboratory of Virology, Department of Virology, Parasitology and
Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan
133, 9820 Merelbeke, Belgium
Full list of author information is available at the end of the article
© 2012 De Baere et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orArteriviridae, in the order Nidovirales [5]. Two distantly
related genotypes exist: the European genotype (type I)
and the North American genotype (type II) [6,7]. Within
each genotype a high degree of genetic variability has been
described [8,9], which led to the recent proposal to subdiv-
ide the European genotype into different subtypes [10,11].
Different PRRSV isolates also display a remarkable anti-
genic and pathogenic variability. Their virulence ranges
from apathogenic or moderately virulent, to highly patho-
genic, like the recently emerging type II isolates described
in China [12] and the type I subtype III isolate PRRSV
(Lena), originating from Belarus [13].
PRRSV shows a restricted in vivo host tropism, infecting
pigs only, as well as a restricted cell tropism for cells of
the monocyte/macrophage lineage. The latter is reflected
by the specific infection of subsets of macrophages that
are mainly present in lungs, lymphoid tissues and placenta
[14,15], with alveolar macrophages being major target cellsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in lysis or apoptosis of infected cells and apoptosis of un-
infected bystander cells [17-20]. In previous studies
[21,22], a decrease in the number of alveolar macrophages
was found up to 9 days post infection, with a maximum
decrease of 35–40%, followed by a marked increase up to
52 days post infection, resulting from replacement of these
cells by infiltrating monocytes, which are known to differ-
entiate into macrophages. Since alveolar macrophages are
the predominant cells involved in the innate defence in
the lungs [23], PRRSV infection impacts the respiratory
immune system of the pig early in infection. The virus is
associated with respiratory problems in pigs of all ages, is
known to predispose pigs to secondary infections, and is
commonly isolated on farms with porcine respiratory dis-
ease complex (PRDC) [24].
PRRSV shows a tropism for specific subsets of differen-
tiated macrophages [14], which is conferred by the presence
of certain entry mediators. As reviewed by Van Breedam
et al. [25], three entry mediators are known to be involved
in the entry pathway of PRRSV in macrophages: 1) heparan
sulphate glycosaminoglycans serve as PRRSV attachment
factors involved in the initial binding and concentration of
the virus on the macrophage surface; 2) the siglec siaload-
hesin (Sn) interacts with sialic acids present on the virus,
which leads to a more stable binding, and results in
internalization of the virus together with its receptor; 3)
scavenger receptor CD163 is implicated in virus uncoating
and genome release. It is established that Sn functions as a
clathrin-dependent endocytic receptor that can be tar-
geted by Sn-specific immunotoxins to kill macrophages
and by Sn-specific antigen immunoconjugates as a vac-
cination strategy improving antibody responses [26].
Also, in a recent study it was shown that antibody
binding to porcine Sn causes a decrease in phagocytic
capacity of primary alveolar macrophages (PAM) [27]. It
was suggested that the interaction of other ligands with
Sn might also result in an impaired phagocytic capacity
of PAM. Considering the reported increase in secondary
bacterial infections following PRRSV infection, the
downregulating effect of antibody binding to Sn on
macrophage phagocytosis and the fact that PRRSV inter-
acts with Sn, we wondered whether PRRSV binding to Sn
might likewise result in a decreased phagocytic capacity
of PAM. Therefore, this study aimed to assess whether
the interaction of European genotype PRRSV with PAM
affects their phagocytic capacity, and whether interaction
with its entry mediators Sn and/or CD163 mediates the
inhibitory effect of PRRSV on PAM phagocytosis.
Materials and methods
Cells
PAM were obtained from 4- to 6-week-old conventional
Belgian Landrace pigs from a PRRSV-negative herd aspreviously described [2]. PAM and Marc-145 cells were
cultivated as described by Van Gorp et al. [28].
Viruses
Marc-145-grown virus: a 4th passage was used for the fol-
lowing PRRSV strains: 1) genotype I, subtype I prototype
PRRSV strain, Lelystad virus (LV), that was first passaged
on macrophages for 12 passages [2]; 2) genotype I, subtype
III prototype PRRSV strain Lena, that was adapted on
Marc-145 cells as described [13]. For concentration and
inactivation, a 5th passage of PRRSV (LV), that was first
passaged on macrophages for 12 passages, was used.
Macrophage-grown virus: a 13th passage of PRRSV (LV)
and a 4th passage of PRRSV (Lena) was used. For concen-
tration, a 14th passage of PRRSV (LV) and a 4th passage of
PRRSV (Lena), were used. Virus titrations and calculations
of the virus titres (TCID50 values) were performed as
described before [28]. For each experiment, virus titrations
were performed on macrophages from the same batch as
the batch used in the respective experiment. Virus was
concentrated from the supernatant after filtration through
a 0.45 μm filter (Sarstedt, Nümbrecht, Germany) as previ-
ously described [29]. Virus inactivation through treatment
with binary ethylenimine (BEI; Sigma-Aldrich, St. Louis,
MO, USA) or with ultraviolet (UV) radiation was per-
formed and verified as described before [29], always con-
firming complete inactivation.
Antibodies
The IgG1 porcine Sn-specific mouse monoclonal anti-
body (mAb) 41D3 was used as a ligand to bind Sn
[30,31]. The IgG1 porcine CD163-specific mouse mAb
2A10 (AbD Serotec, Kidlington, UK; MCA2311) or a
human CD163-specific goat polyclonal antibody (pAb)
(R&D Systems, Minneapolis, MN, USA), which is known
to cross-react with porcine Sn, were used as ligands to
bind CD163 [28,32,33]. Isotype-matched irrelevant mAb
13D12, directed against pseudorabies virus glycoprotein
gD [34], and purified goat antibodies were used as con-
trols. MAb 41D3 and 13D12 were purified using protein
G column chromatography (GE Healthcare, VWR, Leu-
ven, Belgium) following the manufacturers’ instructions.
PRRSV virions were visualized via the nucleocapsid pro-
tein-specific mAb 13E2 [35].
Phagocytosis assays
To assess the effect of PRRSV or Sn- and CD163-spe-
cific antibodies on PAM phagocytosis, macrophages
were inoculated with PRRSV or antibodies 24 h post
seeding and further incubated for 1 h, after which a
phagocytosis assay was performed. In a first experiment
PAM were inoculated with macrophage- or Marc-145-
grown virus at a multiplicity of infection (moi) of 0.3, 1,
3, or 5 for PRRSV (LV) or an moi of 0.3, 1, 3, 5, 10 or 30
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between the TCID50 value and the number of cells. As a
control, PAM were mock-infected with macrophage- or
Marc-145-supernatant of cells that were cultured for
5 days. In a second experiment PAM were inoculated
with an moi of 0.1, 0.3, 1, 3, 10 or 30 of concentrated
Marc-145-grown PRRSV (LV) or equal amounts of con-
centrated and inactivated Marc-145-grown PRRSV (LV).
As a control, PAM were mock-infected with RPMI con-
taining 10% PBS, which is the medium in which the con-
centrated virus is dissolved (and inactivated). As a
control for the effect of the BEI-treatment of the virus
on PAM phagocytosis, cells were mock-infected with
BEI-treated RPMI containing 10% PBS, showing no ef-
fect on phagocytosis. In a third experiment PAM were
inoculated with 0.15, 0.5, 1.5, 5, 15, 50 μg/mL mAb
41D3, 2A10 or 13D12 or the CD163-specific pAb. As a
control, PAM were inoculated with PBS in the absence
of mAbs. Also, for every experiment a phagocytosis
assay was performed at 4°C, following mock-infection, to
determine the number of beads bound to the cell sur-
face. Phagocytosis assays using fluorescent beads were
performed in suspension and were analyzed by flow
cytometry following a propidium iodide (Molecular
Probes, Eugene, OR, USA) live-dead staining as
described before [27]. Data were gated on FSC and SSC
to remove debris from the analysis and on FL-2 to ex-
clude non-viable cells from the analysis. The percentage
of viable PAM phagocytosing beads and their MFI (me-
dian fluorescence intensity), which is a measure for the
number of beads present per cell, was determined. Con-
focal microscopical pictures were generated as described
before [27], including a staining for PRRSV particles
using 13E2 as primary antibody, followed by goat-anti-
mouse-FITC.
Analysis of virus internalization in PAM
Twenty-four hours post seeding, adherent cells were
washed once with RPMI-1640 (Gibco, Invitrogen, Carls-
bad, CA, USA) followed by inoculation with different
PRRSV strains at an moi of 1. Inoculated cells were incu-
bated for 1 h at 37°C in the presence of the virus. After
virus removal, cells were washed 3 times to remove un-
bound virions and an immunofluorescence staining was
performed as described before [29,36]. Virus
internalization in PAM was analyzed as previously
described [29,36], analyzing at least 20 cells per sample.
Statistics
For each experiment, PAM and virus from the same
batch were used and each experiment was independently
performed at least three times. Results are expressed as
mean ± error of the mean (SEM). Statistical data analysis
was performed using the GraphPad PRISM softwarepackage (v 5.0; La Jolla, CA, USA) using an unpaired t-
test (analysis of the number of virions for macrophage-
and Marc-145-grown PRRSV strains) or a paired t-test
for all other analyses. P values< 0.05 were considered
significant (* p< 0.05; ** p< 0.01; *** p< 0.001).
Results
European genotype PRRSV downregulates the phagocytic
capacity of PAM, depending on the number of
internalized virions
European genotype PRRSV downregulates the phagocytic
capacity of PAM
To study whether European genotype PRRSV has an im-
pact on phagocytosis by PAM, cells were inoculated with
PRRSV (LV) and PRRSV (Lena) at various moi and further
incubated at 37°C for 1 h, after which a phagocytosis assay
was performed. Only viable macrophages were included in
the flow cytometric analysis. Interaction of both PRRSV
strains with PAM causes a reduction in phagocytosis by
PAM (Figure 1A and 1B). For PRRSV (LV) this inhibition
is observed, even though not statistically significant
(p= 0.11 for macrophage-grown and p=0.06 for Marc-
145-grown PRRSV (LV) at an moi of 5). The analysis
shows that both the percentage of macrophages phagocyt-
osing beads (Figure 1A) and the number of beads phago-
cytosed per macrophage, expressed as MFI (Figure 1B),
are downregulated. This observation is independent from
the cell type on which the virus is grown, since both
Marc-145- and macrophage-grown PRRSV strains are able
to inhibit the phagocytic capacity of PAM.
The amount of internalized PRRSV virions corresponds with
the degree of European genotype PRRSV inhibition of PAM
phagocytic capacity
Since the European genotype PRRSV inoculums used in
the previous experiment contain both infectious and non-
infectious virions and since the multiplicity of infection,
which was calculated as the ratio between the TCID50
value and the number of cells, does not take into account
the absolute number of virions entering a cell, we won-
dered whether a difference in the number of internalized
virions corresponds with a difference in inhibition of PAM
phagocytosis. To investigate this, an internalization experi-
ment was performed (Figure 1C). Internalized or surface
bound virions were never observed after mock infection.
Interestingly, a higher number of bound and internalized
virions corresponds with a higher reduction in phagocyt-
osis for macrophage- and Marc-145-grown PRRSV (LV)
and PRRSV (Lena) (Figure 1A and 1B). For macrophage-
grown strains, PRRSV (LV) has a lower number of bound
and internalized virions compared to PRRSV (Lena). This
results in an inhibition of phagocytosis only starting from
an moi of 5, whereas PRRSV (Lena) inhibits phagocytosis
starting from an moi of 1. On the other hand, for Marc-
Figure 1 European genotype PRRSV downregulates PAM phagocytic capacity, depending on the number of internalized virions. Flow
cytometric analysis of the effect of European genotype PRRSV entry on PAM phagocytosis and confocal microscopical analysis of the number of
internalized PRRSV virions per PAM for Marc-145- and macrophage-grown PRRSV (LV) (Black circle) or PRRSV (Lena) (Grey circle): (A–B) The effect
of both PRRSV strains on phagocytosis of beads by viable macrophages, expressed as the percentage of viable cells that have beads associated
with them (A) or the MFI per viable cell (B), which is a measure for the amount of beads per cell. PAM were inoculated with both PRRSV strains
at different moi as indicated and infection was allowed for 1 h, after which a phagocytosis assay was performed. Mock infected cells were
included as a positive control. In addition, a phagocytosis assay was performed at 4°C (dotted line) after mock infection, to assess the percentage
of macrophages that have beads bound to their surface and their MFI. Data represent the mean ± SEM of 3 independent experiments; (C) PAM
were inoculated with both PRRSV strains (moi = 1) and further incubated for 1 h, after which the number of virions per PAM was determined by
an immunofluorescence staining. At least 20 cells were analyzed per sample. Data represent the mean ± SEM of 1 representative experiment.
*p< 0.05; **p< 0.01; ***p< 0.001.
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bound and internalized virions compared to PRRSV
(Lena) and inhibits phagocytosis starting from an moi of
3, compared to an moi of 10 for PRRSV (Lena).
As a control, to assess whether administering higher
numbers of virions leads to a higher reduction in phago-
cytosis, macrophage-grown PRRSV (LV) and PRRSV
(Lena) were concentrated. PAM were inoculated with con-
centrated macrophage-grown PRRSV (LV) (moi = 10) or
PRRSV (Lena) (moi = 100) and further incubated at 37°C
for 1 h, after which a phagocytosis assay was performed.
Indeed, phagocytosis of PAM infected with PRRSV (LV)
(moi = 10) was further reduced down to 42%, compared to
68.3% for mock-infected PAM. Phagocytosis of PAM
infected with PRRSV (Lena) (moi = 100) was reduced
down to 9.4%, which equals the percentage observed when
the assay was performed at 4°C (10%), when active intra-
cellular uptake is blocked, yet passive surface adsorption
of beads proceeds normally. Therefore, it can be specu-
lated that phagocytosis of PAM is completely blocked
when PAM are infected with an moi of 100 of macro-
phage-grown PRRSV (Lena).
From these experiments we conclude that the effect of
European genotype PRRSV on phagocytosis is determined
by the total number of internalized virions. We suggest
that both infectious and non-infectious virus contribute to
the effect of European genotype PRRSV on phagocytosis,
since at the same moi, the amount of internalized virions
seems to determine the reduction in phagocytosis.
European genotype PRRSV does not need to be infectious
to downregulate PAM phagocytic capacity
Since the number of internalized virions appears to correl-
ate with reduction in phagocytosis, it was investigated
whether infectious PRRSV virions are needed for the in-
hibitory effect of European genotype PRRSV on PAM
phagocytosis. Concentrated Marc-145-propagated PRRSV
(LV) was BEI-inactivated, obtaining PRRSV virions that are
able to bind and enter PAM similar to non-inactivated vir-
ions [29], without causing a productive infection. PAM
were inoculated with either infectious or BEI-inactivated
virus at different moi and further incubated at 37°C for
1 h, after which the effect on phagocytosis was studied
(Figure 2). From our results, it is clear that BEI-inactivated
PRRSV (LV) caused a similar reduction in phagocytosis as
non-inactivated, infectious PRRSV (LV). In both cases, the
percentage PAM phagocytosing beads (Figure 2A) and the
number of beads phagocytosed per PAM (Figure 2B) was
reduced starting from an moi of 3 and was further reduced
when higher moi were administered. At an moi of 30, the
percentage PAM phagocytosing beads was reduced down
to the percentage observed when the assay was performed
at 4°C (27.9± 0.6%), when active intracellular uptake is
blocked, yet passive surface adsorption of beads proceedsnormally. At this point, the number of beads per PAM was
a little higher than at 4°C, as observed by MFI. This sug-
gests that the phagocytic capacity of PAM is completely
blocked at this point, even though more beads are bound
at the cell surface. Similar results were obtained when UV-
inactivated virus was used (data not shown). Hence, these
findings show that the virus does not need to be infectious
to cause a reduction in phagocytic capacity of PAM and it
can therefore be assumed that binding and internalization
of European genotype PRRSV virions into PAM is suffi-
cient to reduce phagocytosis, without the need for viral
replication. Figure 2c shows representative images which
visualize that when a higher moi is administered, more
viral particles have entered the cells and phagocytosis
decreases.
Ligand binding to sialoadhesin, but not CD163,
downregulates phagocytosis
Since inactivated virus also downregulates phagocytosis,
the process causing this downregulation is not a replica-
tive viral process, and probably results from a cellular
process initiated upon interaction of the virus with the
cell. Therefore we investigated whether the downregula-
tion of phagocytosis could be explained by the inter-
action of the virus with its entry mediators Sn and/or
CD163. To do so, another phagocytosis assay was per-
formed. PAM were incubated with different concentra-
tions of an Sn-specific mAb, a CD163-specific mAb or
an isotype-matched control mAb for 1 h, after which the
effect on phagocytosis was studied (Figure 3). Incubation
of PAM with the Sn-specific mAb caused a downregula-
tion of phagocytosis, starting from the lowest dose
tested, affecting both the percentage of macrophages
phagocytosing beads (Figure 3a) and the number of
beads taken up per PAM (Figure 3b). PAM phagocytic
capacity was further reduced when higher doses of the
Sn-specific mAb were administered, up to 1.5 μg/mL, at
which point phagocytosis was reduced down to the level
observed when the assay was performed at 4°C, for both
the percentage of PAM phagocytosing beads and the
number of beads taken up per PAM. Further increasing
the antibody dose did not further reduce the phagocytic
capacity of PAM. This suggests that the phagocytic cap-
acity of PAM is completely blocked when 1.5 μg/mL of
the Sn-specific mAb is administered. Interestingly, the
CD163-specific mAb 2A10 had no effect on phagocyt-
osis, even at concentrations 30 times higher than the
dose at which the Sn-specific mAb showed a maximum
effect on phagocytosis. Similarly, experiments performed
with a polyclonal antibody against CD163 also showed
no effect on PAM phagocytosis (data not shown). In
both cases, the effect of the CD163-specific antibodies
was comparable to the effect of the isotype-matched
control mAb treated or non-treated cells. Our data show
Figure 2 European genotype PRRSV does not need to be infectious to downregulate PAM phagocytic capacity. (A–B) Flow cytometric
analysis of the role of PRRSV infectivity in the inhibitory effect of European genotype PRRSV on macrophage phagocytosis: The effect of Marc-
145-grown infectious (Black circle) and BEI-inactivated (Grey circle) concentrated PRRSV (LV) on phagocytosis of beads by viable macrophages,
expressed as the percentage of viable cells that have beads associated with them (A) or the MFI per viable cell (B), which is a measure for the
amount of beads per cell. PAM were inoculated with infectious or inactivated PRRSV (LV) at different moi as indicated and further incubated at
37°C for 1 h, after which a phagocytosis assay was performed. Mock infected cells were included as a control. Also, a phagocytosis assay was
performed at 4°C (dotted line) after mock infection, to assess the percentage of macrophages that have beads bound to their surface and their
MFI. Data represent the mean ± SEM of 4 independent experiments. *p< 0.05; ** p< 0.01; *** p< 0.001; (C) Confocal microscopical
representation of the inhibitory effect of European genotype PRRSV on macrophage phagocytosis: the effect of Marc-145-grown, concentrated
PRRSV (LV) on phagocytosis of beads by viable macrophages (performed as described above). An immunofluorescence staining was performed
following the phagocytosis assay. Mock infected cells were included as a control and a phagocytosis assay was performed at 4°C after mock
infection. For each moi, 4 single confocal z-sections throughout the middle of the cell are given, representative of each situation. Yellow-green
fluorescent beads were used, nuclei are stained with Hoechst 33342 (blue), PRRSV virions are shown in green and cortical actin is visualized using
TexasRed-X phalloidin. Upper panel: PAM phagocytosis of beads; Lower panel: internalized PRRSV particles.
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leads to a similar inhibitory effect on PAM phagocytosis
as observed after PAM inoculation with European geno-
type PRRSV, which suggests the involvement of Sn in
the previously observed downregulation of phagocytosis
by European genotype PRRSV. Our findings indicate
that the observed downregulation of phagocytosis upon
European genotype PRRSV inoculation is due to the
interaction of the virus with its receptor Sn, but not
CD163.
Discussion
The present study shows that interaction of European
genotype PRRSV with macrophages causes a clearreduction in macrophage phagocytic capacity, reducing
both the number of macrophages phagocytosing beads
and the number of beads taken up per cell. Using inacti-
vated PRRSV (LV), we show that the observed downre-
gulation of phagocytosis results from binding of PRRSV
virions and their subsequent internalization, without
the need for viral replication. This is supported by the
fact that a higher number of internalized virions corre-
sponds to a higher decrease in phagocytic capacity, both
for Marc-145-grown and macrophage-grown virus. Fi-
nally, we suggest that the extracellular interaction of
European genotype PRRSV with its receptor Sn, but not
CD163, inhibits primary alveolar macrophage phagocyt-
osis at the early stage of virus entry.
Figure 3 Antibody binding to sialoadhesin, but not CD163, downregulates phagocytosis. Flow cytometric analysis of the effect of Sn- or
CD163-specific antibodies on macrophage phagocytosis. The effect of the Sn-specific mAb 41D3 (Black circle), the CD163-specific mAb 2A10
(Dark grey circle) or an isotype-matched control mAb 13D12 (Light grey circle) on phagocytosis of beads by viable macrophages, expressed as
the percentage of viable cells that have beads associated with them (A) or the MFI per viable cell (B), which is a measure for the amount of
beads per cell. PAM were incubated with the indicated amount of mAb for 1 h, after which a phagocytosis assay was performed. As a control,
non-treated PAM were included in the study. In addition, a phagocytosis assay was performed at 4°C (dotted line) with non-treated cells, to
assess the percentage of macrophages that have beads bound to their surface and their MFI. Data represent the mean ± SEM of 3 independent
experiments. *p< 0.05; **p< 0.01; ***p< 0.001.
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inoculation further supports our reasoning that the
reduced phagocytic capacity is not merely due to virus-
induced macrophage death, as often stated, and that the
interaction of the PRRSV virion with its target cell is suf-
ficient to reduce PAM phagocytosis. From previous re-
search it is know that PRRSV has a replication cycle of
approximately 12 h, after which the virus is released
from the cell, thereby killing its target cell [37]. More-
over, it was shown that early in infection, PRRSV pro-
motes anti-apoptotic pathways in PAM, up to 8 h post
infection. Thus, at 1 h post infection, no virus-induced
cell death occurs and therefore the decrease in phagocyt-
osis cannot be explained by virus-induced cell-death.
It is known that 1 h post infection, internalized virions
can still be observed, whereas 5 h post infection, virions
can no longer be detected [38], which indicates that all
virions are uncoated. Starting from 6 h post infection,
newly synthesized structural proteins can be detected
[39]. Consequently, this supports our finding that entry
of the virus into the cell, but not production of progeny
virus, causes the inhibition of phagocytosis.
Our study shows that a 1 h incubation of PAM with
an Sn-specific mAb results in a decreased phagocytic
capacity of PAM, whereas incubation with a CD163-spe-
cific mAb or pAb has no effect. Both Sn and CD163 are
present at the cell surface and therefore available for
antibody-binding. In addition, it was previously shown
that incubation of PAM with any of these antibodies
blocks infection of PRRSV, indicating that they canprevent interaction of the virus with their respective
receptors ([28,30]; H. Van Gorp, unpublished data).
Moreover, at the highest administered dose, still no ef-
fect on PAM phagocytic capacity of the CD163-specific
antibodies was observed. This concentration was 33
times higher than the dose at which phagocytosis was
completely blocked with the Sn-specific mAb. Therefore,
we conclude that the interaction of European genotype
PRRSV with its receptor Sn, but not CD163, inhibits pri-
mary alveolar macrophage phagocytosis.
Recent studies investigating the functional role of por-
cine Sn (pSn) have demonstrated that pSn is an endocytic
receptor that mediates endocytosis of PRRSV or anti-
bodies upon binding [26,31]. pSn was also shown to in-
duce signalling [40] and reduce phagocytosis [27] in PAM
upon antibody binding. Therefore, it was suggested that
antibody binding to pSn activates certain molecular net-
works, which results in the downregulation of pathways
involved in phagocytosis. This might also explain how the
extracellular interaction of European genotype PRRSV
with Sn downregulates phagocytosis. The results obtained
in our study indicate that a certain number of virions need
to interact with Sn before a certain ligand-receptor signal-
ling threshold is reached and PAM get activated. In this
scenario, the interaction of the virion with Sn serves as a
trigger for further signalling, leading to a downregulation
of PAM phagocytic capacity. Once this threshold is
reached, administering higher moi, and therefore higher
numbers of virions, results in a further downregulation
of phagocytosis. Ligand-receptor signalling thresholds
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interactions, e.g. the interaction of human immunodefi-
ciency virus (HIV) envelope glycoprotein (Env) with
coreceptor CXCR4 [41] and of viral RNA with TLR7
[42], which must be reached to trigger sufficient activa-
tion of a receptor and subsequent signalling. Moreover,
our results show that the phagocytic capacity of PAM
can be blocked completely when a sufficiently high anti-
body dose or number of European genotype PRRSV
particles (an moi of 30 of Marc-145-grown PRRSV (LV)
or an moi of 100 of macrophage-grown PRRSV (Lena))
is administered. This suggests that once Sn is triggered
sufficiently through ligand binding, whether it is an
antibody or European genotype PRRSV virions, phago-
cytosis is maximally inhibited.
Both for human and mouse Sn it is suggested that alter-
native splicing of the Sn gene produces a transcript variant
encoding an isoform that is soluble rather than mem-
brane-bound [43]. It can be argued that these variants
have no significant role in the downregulation of phago-
cytosis, since these variants are either excreted or present
intracellularly in a non-membrane bound form, whereas
surface-expressed Sn is needed to internalize PRRSV [31],
subsequently downregulating phagocytosis. Moreover, no
porcine splice variants have been reported, and no soluble
Sn variants have so far been observed in vivo.
Interestingly, at an moi of 1, all macrophages have
internalized several PRRSV virions, indicating that many
non-infectious virions are present. This can be due to
storage and thawing of the virus, but it can also be a dir-
ect result from the high mutation frequency reported for
PRRSV [44,45]. If these mutations occur at crucial sites
in the genome, the progeny virus will still be able to
enter its target cell, but will have lost its ability to repli-
cate upon uncoating and genome release. This observa-
tion is of importance if the observed inhibition of
phagocytosis upon European genotype PRRSV infection
also occurs in vivo, since non-infectious progeny virus is
also present in the lungs of pigs, and can contribute to
the downregulation of PAM phagocytic capacity.
Several other viruses have been shown to affect phagocyt-
osis. Respiratory syncytial virus and secondary dengue virus
infections have been shown to increase macrophage phago-
cytosis [46,47]. On the other hand, HIV, pseudorabies virus
and influenza virus [48-50] infections are known to sup-
press phagocytosis, and in all cases this suppression is
linked to an increased incidence of secondary infections.
The way in which these viruses downregulate phagocytosis
differs for each virus. For HIV for instance, one of the
mechanisms causing the decreased phagocytosis in neutro-
phils and monocytes/macrophages is through the inter-
action of the cell with certain viral proteins, such as gp 120,
p24 and Nef. It is difficult to comment on the relative moi
at which phagocytosis is affected in these studies versus themoi at which European genotype PRRSV downregulates
PAM phagocytosis. This is either due to different defini-
tions of moi used in each study, such as egg infectious dose
(EID50) or plaque forming units (PFU), or because persist-
ently infected cells or cells isolated from infected indivi-
duals or animals were used and no moi was determined. It
could be argued that the observed downregulation of PAM
phagocytosis in our study occurs at relatively high moi,
however, it is difficult to assess which moi are reached in
the lungs of pigs in vivo. For PRRSV (Lena), titers of up to
107.8 have been reported in BAL (bronchoalveolar lavage)
fluids [13], corresponding to an moi of 63, and it can be
argued that the effective titers in the lungs will be even
higher, due to freeze/thawing and storage procedures.
PRRSV is a major player in porcine respiratory disease
complex (PRDC) (reviewed by [24,51]). Field reports and
clinical evidence demonstrate an increased incidence
and severity of secondary infections associated with pri-
mary PRRSV infections. Strikingly, the direct effect of
the virus on macrophage phagocytosis during the early
stages of infection is poorly studied. Whereas some
authors report that PRRSV infection has no effect on the
uptake of Staphylococcus aureus [52] and Escherichia
coli [53], other authors report an impaired phagocytic
capacity against Candida albicans [54], Salmonella
typhimurium [55], and Haemophilus parasuis [56],
which supports our findings. Importantly, all of these
studies showed, like we did, that virus-induced cell death
was not involved. One of the factors influencing the out-
come of these experiments is the secondary pathogen,
and specific isolate, used. Each pathogen interacts with
PAM in a different way and each secondary infection
might have an additional immunomodulatory effect on
PAM. Therefore, in our study, polystyrene beads were
used as a reproducible, inert model to study the effect of
European genotype PRRSV on PAM phagocytosis. Add-
itionally, different PRRSV isolates might influence the
outcome of each experiment, which was not the case for
the two isolates used in this study. Yet, preliminary
results indicate possible divergent effects of North
American genotype PRRSV isolates on PAM phagocyt-
osis (data not shown), which we are investigating in an
ongoing study.
In a previous study, Van Gucht et al. [57] showed that
infection with PRRSV sensitizes the lungs for production
of proinflammatory cytokines upon exposure to lipopoly-
saccharides (LPS) and demonstrated that overproduction
of these cytokines led to respiratory disease. If the
observed inhibition of phagocytosis upon European geno-
type PRRSV infection also occurs in vivo, higher amounts
of LPS will be present in the lungs after infection, since re-
moval of secondary or opportunistic bacteria, and thus
bacterial endotoxins, from the alveolar space will be
affected. This could lead to a further exacerbation of
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This might also explain why an uncomplicated PRRSV in-
fection often fails to induce overt respiratory disease [58],
although PRRSV is a primary agent in PRDC.
To our knowledge, the present study is the first to show
a direct effect of European genotype PRRSV on PAM
phagocytic capacity in vitro, linking it to the interaction of
the virus with its target cell, and more specific with its at-
tachment and internalization receptor Sn. If similar events
occur in vivo, this contributes to the reported increase and
severity of secondary bacterial infections following Euro-
pean genotype PRRSV infection and the prevalence of
European genotype PRRSV in porcine respiratory disease
complex (PRDC).
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